Suoyu S Xu
Overview
Explore the profile of Suoyu S Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McLaren D, Previs S, Phair R, Stout S, Xie D, Chen Y, et al.
J Lipid Res
. 2015 Dec;
57(3):398-409.
PMID: 26658238
Studies in lipoprotein kinetics almost exclusively rely on steady-state approaches to modeling. Herein, we have used a non-steady-state experimental design to examine the role of cholesteryl ester transfer protein (CETP)...
2.
Lu Z, Chen Y, Napolitano J, Taylor G, Ali A, Hammond M, et al.
Bioorg Med Chem Lett
. 2011 Dec;
22(1):199-203.
PMID: 22142541
SAR studies of the substitution effect on the central phenyl ring of the biphenyl scaffold were carried out using anacetrapib (9a) as the benchmark. The results revealed that the new...
3.
Smith C, Ali A, Hammond M, Li H, Lu Z, Napolitano J, et al.
J Med Chem
. 2011 Jun;
54(13):4880-95.
PMID: 21682257
The development of the structure-activity studies leading to the discovery of anacetrapib is described. These studies focused on varying the substitution of the oxazolidinone ring of the 5-aryloxazolidinone system. Specifically,...
4.
Kallashi F, Kim D, Kowalchick J, Park Y, Hunt J, Ali A, et al.
Bioorg Med Chem Lett
. 2010 Nov;
21(1):558-61.
PMID: 21094047
We describe structure-activity studies leading to the discovery of 2-arylbenzoxazole 3, the first in a series to raise serum high-density lipoprotein cholesterol levels in transgenic mice. Replacement of the 4-piperidinyloxy...
5.
Lu Z, Napolitano J, Theberge A, Ali A, Hammond M, Tan E, et al.
Bioorg Med Chem Lett
. 2010 Nov;
20(24):7469-72.
PMID: 21041082
A new class of CETP inhibitors was designed and prepared. These compounds are potent both in vitro and in vivo. The most active compound (12d) has shown an ability to...
6.
2-Arylbenzoxazoles as CETP inhibitors: substitution and modification of the alpha-alkoxyamide moiety
Hunt J, Gonzalez S, Kallashi F, Hammond M, Pivnichny J, Tong X, et al.
Bioorg Med Chem Lett
. 2009 Dec;
20(3):1019-22.
PMID: 20036121
The development of a series of 2-arylbenzoxazole alpha-alkoxyamide and beta-alkoxyamine inhibitors of cholesteryl ester transfer protein (CETP) is described. Highly fluorinated alpha-alkoxyamides proved to be potent inhibitors of CETP in...
7.
Shen X, Yao Z, Johnson T, Feeney W, Jennings V, Xu S, et al.
Lab Anim (NY)
. 2007 Dec;
37(1):41-4.
PMID: 18094701
One approach to understanding how orally administered drugs are absorbed and metabolized involves measuring compound concentrations in portal vein blood and in systemic circulation at various time points. In mice,...
8.
Fong T, Guan X, Marsh D, Shen C, Stribling D, Rosko K, et al.
J Pharmacol Exp Ther
. 2007 Mar;
321(3):1013-22.
PMID: 17327489
The cannabinoid-1 receptor (CB1R) has been implicated in the control of energy balance. To explore the pharmacological utility of CB1R inhibition for the treatment of obesity, we evaluated the efficacy...
9.
Lin L, Lanza Jr T, Jewell J, Liu P, Shah S, Qi H, et al.
J Med Chem
. 2006 Dec;
49(26):7584-7.
PMID: 17181138
The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction....